329 related articles for article (PubMed ID: 18375410)
1. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
[TBL] [Abstract][Full Text] [Related]
2. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
3. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients.
Luque-Ramírez M; Alvarez-Blasco F; Escobar-Morreale HF
Obesity (Silver Spring); 2009 Jan; 17(1):3-9. PubMed ID: 18997670
[TBL] [Abstract][Full Text] [Related]
5. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations.
Luque-Ramírez M; Escobar-Morreale HF
Horm Metab Res; 2010 Oct; 42(11):815-20. PubMed ID: 20730705
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
8. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
9. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome.
Gul OB; Somunkiran A; Yucel O; Demirci F; Ozdemir I
Arch Gynecol Obstet; 2008 Jan; 277(1):25-30. PubMed ID: 17618446
[TBL] [Abstract][Full Text] [Related]
10. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
11. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
Luque-Ramírez M; Mendieta-Azcona C; del Rey Sánchez JM; Matíes M; Escobar-Morreale HF
Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031
[TBL] [Abstract][Full Text] [Related]
12. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
13. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
14. Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome.
Chen MJ; Yang WS; Chen HF; Kuo JJ; Ho HN; Yang YS; Chen SU
Hum Reprod; 2010 Mar; 25(3):779-85. PubMed ID: 20093255
[TBL] [Abstract][Full Text] [Related]
15. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
[TBL] [Abstract][Full Text] [Related]
16. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA
Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
[TBL] [Abstract][Full Text] [Related]
17. [Combined use of metformin and Diane35 in polycystic ovary syndrome].
Mitkov M; Pekhlivanov B; Terzieva D
Akush Ginekol (Sofiia); 2004; 43(3):34-7. PubMed ID: 15341255
[TBL] [Abstract][Full Text] [Related]
18. Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary.
Vrbikova J; Dvorakova K; Hill M; Starka L
Endocr Regul; 2006 Dec; 40(4):119-23. PubMed ID: 17201585
[TBL] [Abstract][Full Text] [Related]
19. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
Morin-Papunen L; Rautio K; Ruokonen A; Hedberg P; Puukka M; Tapanainen JS
J Clin Endocrinol Metab; 2003 Oct; 88(10):4649-54. PubMed ID: 14557435
[TBL] [Abstract][Full Text] [Related]
20. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.
Jakubowska J; Bohdanowicz-Pawlak A; Milewicz A; Szymczak J; Bednarek-Tupikowska G; Demissie M
Gynecol Endocrinol; 2008 Jul; 24(7):378-84. PubMed ID: 18645710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]